uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia

Source :: GlobeNewswire. March 26, 2020
Publication Year :: 2020
Abstract: LEXINGTON, Mar 26, 2020 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced [...]

Subjects :: United States. Food and Drug Administration
Hemophilia -- Care and treatment
Factor IX -- Product development
Hemophilia B -- Care and treatment
Genes
Time
Clinical trials
Patent law
Banking, finance and accounting industries
Business

Tools